Influence of obesity and insulin sensitivity on insulin signaling genes in human omental and subcutaneous adipose tissue

Journal of Lipid Research

Volumn 49, Issue 2, 2008, Pages 308-323

  MacLaren, R ^a,b   Cui, W ^a,b   Simard, S ^b   Cianflone, K ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Differentiation; Glucose; Insulin resistant obese; Insulin sensitive obese; Proliferation; Protein synthesis

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 2; PROTEIN KINASE B BETA; PROTEIN SERINE THREONINE KINASE; PROTEIN SHC; RAF PROTEIN; RHEB PROTEIN; S6 KINASE; SOS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GLUCOSE TRANSPORT; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SUBCUTANEOUS FAT;

ADULT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OMENTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT;

EID: 38949140543     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700199-JLR200     Document Type: Article

References (48)

1. Alberti, K. G., and P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15: 539-553.
2. Haffner, S. M. 2006. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity. 14 (Suppl. 3): 121-127.
3. Despres, J. P., and I. Lemieux. 2006. Abdominal obesity and metabolic syndrome. Nature. 444: 881-887.
4. Reaven, G. 2005. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diabetes Vasc. Dis. Res. 2: 105-112.
5. Reaven, G., F. Abbasi, and T. McLaughlin. 2004. Obesity, insulin resistance, and cardiovascular disease. Recent Prog. Horm. Res. 59: 207-223.
6. Sims, E. A. 2001. Are there persons who are obese, but metabolically healthy? Metabolism. 50: 1499-1504.
7. St. Pierre, D. H., A. D. Karelis, L. Coderre, F. Malita, J. Fontaine, D. Mignault, M. Brochu, J. P. Bastard, K. Cianflone, E. Doucet, et al. 2007. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. J. Clin. Endocrinol. Metab. 92: 264-269.
8. Karelis, A. D., D. H. St. Pierre, F. Conus, R. Rabasa-Lhoret, and E. T. Poehlman. 2004. Metabolic and body composition factors in subgroups of obesity: what do we know? J. Clin. Endocrinol. Metab. 89: 2569-2575.
9. Brochu, M., A. Tchernof, I. J. Dionne, C. K. Sites, G. H. Eltabbakh, E. A. Sims, and E. T. Poehlman. 2001. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab. 86: 1020-1025.
10. Karelis, A. D., M. Brochu, R. Rabasa-Lhoret, D. Garrel, and E. T. Poehlman. 2004. Clinical markers for the identification of metabolically healthy but obese individuals. Diabetes Obes. Metab. 6: 456-457.
11. Lim, S. C., B. Y. Tan, S. K. Chew, and C. E. Tan. 2002. The relationship between insulin resistance and cardiovascular risk factors in overweight/obese non-diabetic Asian adults: the 1992 Singapore National Health Survey. Int. J. Obes. Relat. Metab. Disord. 26: 1511-1516.
12. Shin, M. J., Y. J. Hyun, O. Y. Kim, J. Y. Kim, Y. Jang, and J. H. Lee. 2006. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int. J. Obes. 30: 1529-1534.
13. Eriksson, J. W., U. Smith, F. Waagstein, M. Wysocki, and P. A. Jansson. 1999. Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes. 48: 1572-1578.
14. Laviola, L., S. Perrini, A. Cignarelli, A. Natalicchio, A. Leonardini, F. De Stefano, M. Cuscito, M. De Fazio, V. Memeo, V. Neri, et al. 2006. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes. 55: 952-961.
15. Bolinder, J., L. Kager, J. Ostman, and P. Arner. 1983. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 32: 117-123.
16. Maslowska, M. H., A. D. Sniderman, L. D. MacLean, and K. Cianflone. 1993. Regional differences in triacylglycerol synthesis in adipose tissue and in cultured preadipocytes. J. Lipid Res. 34: 219-228.
17. Hube, F., M. Birgel, Y. M. Lee, and H. Hauner. 1999. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 29: 672-678.
18. Hube, F., U. Lietz, M. Igel, P. B. Jensen, H. Tornqvist, H. G. Joost, and H. Hauner. 1996. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm. Metab. Res. 28: 690-693.
19. Williams, L. B., R. L. Fawcett, A. S. Waechter, P. Zhang, B. E. Kogon, R. Jones, M. Inman, J. Huse, and R. V. Considine. 2000. Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J. Clin. Endocrinol. Metab. 85: 2678-2684.
20. Richelsen, B., S. B. Pedersen, T. Moller-Pedersen, and J. F. Bak. 1991. Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism. 40: 990-996.
21. Dicker, A., M. Ryden, E. Naslund, I. E. Muehlen, M. Wiren, M. Lafontan, and P. Arner. 2004. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 47: 420-428.
22. Hoffstedt, J., P. Arner, G. Hellers, and F. Lonnqvist. 1997. Variation in adrenergic regulation of lipolysis between omental and subcutaneous adipocytes from obese and non-obese men. J. Lipid Res. 38: 795-804.
23. James, W. P., N. Rigby, and R. Leach. 2006. Obesity and the metabolic syndrome: the stress on society. Ann. N. Y. Acad. Sci. 1083: 1-10.
24. Lefebvre, A. M., M. Laville, N. Vega, J. P. Riou, L. van Gaal, J. Auwerx, and H. Vidal. 1998. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes. 47: 98-103.
25. Capeau, J. 2003. [Insulin signaling: mechanisms altered in insulin resistance.] Med. Sci. (Paris). 19: 834-839.
26. Kido, Y., J. Nakae, and D. Accili. 2001. Clinical review 125. The insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab. 86: 972-979.
27. Jones, K. L., S. S. King, and M. J. Iqbal. 2004. Endophyte-infected tall fescue diet alters gene expression in heifer luteal tissue as revealed by interspecies microarray analysis. Mol. Reprod. Dev. 67: 154-161.
28. Tusher, V. G., R. Tibshirani, and G. Chu. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA. 98: 5116-5121.
29. Karelis, A. D., M. Brochu, and R. Rabasa-Lhoret. 2004. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 30: 569-572.
30. Sucharda, P. 1989. [Clinical significance of the quantification of obesity. The Quetelet index and its use.] Cas. Lek. Cesk. 128: 1040-1043.
31. Expert Committee. 2003. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 26 (Suppl.): 5-20.
32. Gorzelniak, K., J. Janke, S. Engeli, and A. M. Sharma. 2001. Validation of endogenous controls for gene expression studies in human adipocytes and preadipocytes. Horm. Metab. Res. 33: 625-627.
33. Zhou, Q. L., J. G. Park, Z. Y. Jiang, J. J. Holik, P. Mitra, S. Semiz, A. Guilherme, A. M. Powelka, X. Tang, J. Virbasius, et al. 2004. Analysis of insulin signalling by RNAi-based gene silencing. Biochem. Soc. Trans. 32: 817-821.
34. Shi, K., K. Egawa, H. Maegawa, T. Nakamura, S. Ugi, Y. Nishio, and A. Kashiwagi. 2004. Protein-tyrosine phosphatase 1B associates with insulin receptor and negatively regulates insulin signaling without receptor internalization. J. Biochem. (Tokyo). 136: 89-96.
35. Ueno, M., J. B. Carvalheira, R. C. Tambascia, R. M. Bezerra, M. E. Amaral, E. M. Carneiro, F. Folli, K. G. Franchini, and M. J. Saad. 2005. Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia. 48: 506-518.
36. Hiratani, K., T. Haruta, A. Tani, J. Kawahara, I. Usui, and M. Kobayashi. 2005. Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem. Biophys. Res. Commun. 335: 836-842.
37. El Chaar, D., A. Gagnon, and A. Sorisky. 2004. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int. J. Obes. Relat. Metab. Disord. 28: 191-198.
38. Skolnik, E. Y., C. H. Lee, A. Batzer, L. M. Vicentini, M. Zhou, R. Daly, M. J. Myers, Jr., J. M. Backer, A. Ullrich, and M. F. White. 1993. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J. 12: 1929-1936.
39. Rosen, E. D. 2005. The transcriptional basis of adipocyte development. Prostaglandins Leukot. Essent. Fatty Acids. 73: 31-34.
40. Seidell, J. C., J. G. Hautvast, and P. Deurenberg. 1989. Overweight: fat distribution and health risks. Epidemiological observations. A review. Infusionstherapie. 16: 276-281.
41. McLaughlin, T., G. Allison, F. Abbasi, C. Lamendola, and G. Reaven. 2004. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism. 53: 495-499.
42. Nguyen, M. T., H. Satoh, S. Favelyukis, J. L. Babendure, T. Imamura, J. I. Sbodio, J. Zalevsky, B. I. Dahiyat, N. W. Chi, and J. M. Olefsky. 2005. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem. 280: 35361-35371.
43. Marette, A., P. Mauriege, B. Marcotte, C. Atgie, C. Bouchard, G. Theriault, L. J. Bukowiecki, P. Marceau, S. Biron, A. Nadeau, et al. 1997. Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women. Diabetologia. 40: 590-598.
44. Montague, C. T., J. B. Prins, L. Sanders, J. Zhang, C. P. Sewter, J. Digby, C. D. Byrne, and S. O'Rahilly. 1998. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes. 47: 1384-1391.
45. Lane, M. D., Q. Q. Tang, and M. S. Jiang. 1999. Role of the CCAAT enhancer binding proteins (C/EBPs) in adipocyte differentiation. Biochem. Biophys. Res. Commun. 266: 677-683.
46. Heilbronn, L., S. R. Smith, and E. Ravussin. 2004. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 28 (Suppl. 4): 12-21.
47. Smith, U. 2002. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance - is insulin resistance initiated in the adipose tissue? Int. J. Obes. Relat. Metab. Disord. 26: 897-904.
48. Takahashi, S., T. Tanaka, T. Kodama, and J. Sakai. 2006. Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol. Res. 53: 501-507.